Breaking Down SG&A Expenses: Novo Nordisk A/S vs Soleno Therapeutics, Inc.

A Tale of Two Companies: SG&A Expenses Over Time

In the world of pharmaceuticals, the strategic allocation of Selling, General, and Administrative (SG&A) expenses can be a game-changer. Novo Nordisk A/S, a global leader in diabetes care, and Soleno Therapeutics, Inc., a niche player in rare diseases, present a fascinating contrast in their financial strategies from 2014 to 2023.

Novo Nordisk's SG&A expenses have surged by over 130% during this period, reflecting its aggressive market expansion and investment in innovation. In 2023, their expenses reached a staggering 61.6 billion, a testament to their global reach and operational scale. Meanwhile, Soleno Therapeutics, with a more focused approach, saw a modest increase of around 360% in SG&A expenses, peaking at 13.5 million in 2023. This growth underscores their commitment to niche markets and targeted therapies.

This comparison highlights the diverse strategies companies employ to navigate the competitive pharmaceutical landscape.